Foresee Pharmaceuticals Co Ltd (6576) fair value: what the stock is really worth
As of Sep 24, 2026: fair value of Foresee Pharmaceuticals Co Ltd TWD 122, price TWD 80.20, upside +52.4%, quality 44 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Foresee Pharmaceuticals Co Ltd for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.
How to read this chart
60‑month range 57.90 TWD – 135.00 TWD · fair‑value band 80.54 TWD – 152.80 TWD · the 80.20 TWD price screens below the 122.24 TWD fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 24, 2026.
Follow Foresee Pharmaceuticals Co in your weekly email
Every Wednesday you see whether Foresee Pharmaceuticals Co is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Foresee Pharmaceuticals Co., Ltd. operates as biopharmaceutical company in the United States, China, and Europe.
Show more
Foresee Pharmaceuticals Co., Ltd. operates as biopharmaceutical company in the United States, China, and Europe. The company's stabilized injectable formulation pipeline includes FP-001, which completed Phase III clinical study for the treatment of advanced stage prostate cancer; FP-004 that is in preclinical stage to treat opioids use disorder; FP-011 and FP-014, a long-acting sustained release dosage form for the treatment of breast cancer/prostate cancer; and FP-016 for the treatment of neurological diseases. Its new chemical entity pipeline products consist of FP-020 to treat sarcoidosis, idiopathic pulmonary fibrosis, and pulmonary emphysema; FP-025, a selective matrix metalloproteinase-12 inhibitor, which is in Phase II clinical trial for the treatment of asthma, chronic obstructive pulmonary diseases, and acute respiratory distress syndrome in COVID-19 patients; and FP-045, a selective aldehyde dehydrogenase (ALDH2) activator that completed Phase I clinical study for the treatment of fanconi anemia, as well as FP-040, an ALDH2 activator to treat central nervous system diseases. The company was incorporated in 2013 and is headquartered in Taipei, Taiwan.
Stock analysis
Foresee Pharmaceuticals Co Ltd (6576) currently trades at 80.20 TWD, while our model-based Fair Value estimate is 122.24 TWD, implying the stock looks roughly 34.4% undervalued today.
Show more
Valuation
How firm this estimate is: it rests on 1 models at a data quality of 95/100, which puts the evidence level at low.
Scenario range: 80.54 TWD (bear) to 152.80 TWD (bull), the price of 80.20 TWD sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 44/100 (below-average quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Foresee Pharmaceuticals Co Ltd reported revenue of 431M TWD in FY2025 versus 226M TWD in FY2021, a compound +17.5%/yr. Reported net income was −883M TWD in FY2025.
Key figures
Market cap 12.6B TWD (≈ $397M) · P/E ratio 668.3 · P/S ratio 26.8 · EPS (TTM) 0.1200 TWD · Net margin 4.8% · Return on equity 2.0% · Return on assets (EBIT) −46.9% · Operating margin −58.2%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 28 out of 100 (low confidence).
What moves the price
The share trades about 8% below its 52-week high and 10% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −8% fair-value upside, at 52%, 6576 screens cheaper than that median.
Fair Value models
Bear 80.54 TWDFair Value 122.24 TWDBull 152.80 TWD
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then (0.0881 TWD per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.57/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+3.0%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+12.7%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+13.4%
Start year 2020 (pandemic)
Revenue growth 8 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+43.7%
’17
’18
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−209.1% (2020) → −199.9% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
Compare Foresee Pharmaceuticals Co Ltd with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 630 stocks
Beats the industry median on 2/10 measures
Overall it trails its industry peers.
Valuation
Quality Score45 · Below median
Fair Value upside+51% · Top 25%
Profitability
Return on equity (TTM)2% · Below median
Return on assets−18% · Bottom 25%
Net margin (TTM)5% · Below median
Operating margin (TTM)−58% · Bottom 25%
Growth and dividend
Revenue growth63% · Top 25%
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Foresee Pharmaceuticals Co Ltd Fair Value". https://www.fairvalue-calculator.com/stock/6576
Frequently asked questions
Is Foresee Pharmaceuticals Co Ltd (6576) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of 122.24 TWD versus a price of 80.20 TWD, about +52% upside (undervalued).
What is the fair value of 6576?
Our model-based fair value for Foresee Pharmaceuticals Co Ltd is 122.24 TWD (as of Sep 24, 2026), built from audited fundamentals. The current price: 80.20 TWD.
What is the quality score of 6576?
Foresee Pharmaceuticals Co Ltd has a Quality Score of 44/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Foresee Pharmaceuticals Co Ltd (6576)?
Our model-based price target is the fair value of 122.24 TWD (as of Sep 24, 2026) from 1 valuation models. Cautious scenario 80.54 TWD, optimistic scenario 152.80 TWD. It is a calculation from audited fundamentals, not an analyst target.
What is the Foresee Pharmaceuticals Co Ltd stock forecast for 2026?
Our models put fair value at 122.24 TWD, about +52% upside versus a price of 80.20 TWD (undervalued). Cautious scenario 80.54 TWD, optimistic scenario 152.80 TWD. The calculation is refreshed regularly with new filings.
What is the revenue of Foresee Pharmaceuticals Co Ltd (6576)?
Foresee Pharmaceuticals Co Ltd reported trailing-twelve-month revenue of about 471M TWD (latest available figure, as of Sep 24, 2026).
What is the intrinsic value of Foresee Pharmaceuticals Co Ltd (6576)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Foresee Pharmaceuticals Co Ltd it is 122.24 TWD per share (as of Sep 24, 2026), against a price of 80.20 TWD. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Foresee Pharmaceuticals Co Ltd stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 6576 trades below its calculated fair value: price 80.20 TWD, fair value 122.24 TWD, a gap of about +52% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 6576?
No. The price is what the market pays today (80.20 TWD); the fair value is what the company's own numbers justify (122.24 TWD). For Foresee Pharmaceuticals Co Ltd the two are 42.04 TWD per share apart. That gap is exactly why we show both numbers side by side.
How much is Foresee Pharmaceuticals Co Ltd worth?
The market values Foresee Pharmaceuticals Co Ltd at about 12.6B TWD (market capitalisation, as of Sep 24, 2026). Per share that is 80.20 TWD; our models calculate a fair value of 122.24 TWD per share.
What do the bullish and bearish scenarios say about 6576?
Our models span a range for Foresee Pharmaceuticals Co Ltd: cautious scenario 80.54 TWD, base 122.24 TWD, optimistic 152.80 TWD per share (as of Sep 24, 2026, price 80.20 TWD). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Foresee Pharmaceuticals Co Ltd (6576)?
Balance-sheet figures for Foresee Pharmaceuticals Co Ltd (as of Sep 24, 2026): return on equity 2.0%. They feed the Quality Score of 44/100, which measures business quality independently of the share price.
How far is 6576 from its 52-week high?
Foresee Pharmaceuticals Co Ltd trades at 80.20 TWD, about 8% below its 52-week high of 87.30 TWD and 10% above the low of 72.90 TWD (as of Sep 24, 2026). Distance from the high says nothing about value: that is what the fair value of 122.24 TWD is for.
Which stocks are comparable to Foresee Pharmaceuticals Co Ltd?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Jiangsu Hengrui Pharmaceuticals Co, Sun Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Foresee Pharmaceuticals Co Ltd stock attractive at the current price?
The data as of Sep 24, 2026: price 80.20 TWD, calculated fair value 122.24 TWD (+52%), Quality Score 44/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 6576 calculated?
We run Foresee Pharmaceuticals Co Ltd through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 122.24 TWD, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0 % above its aggregate fair value. Foresee Pharmaceuticals Co Ltd currently trades 52 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Foresee Pharmaceuticals Co Ltd (6576)?
The closing price on Sep 24, 2026 was 80.20 TWD. Our model-based fair value is 122.24 TWD, about +52% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Foresee Pharmaceuticals Co Ltd right now?
The large discount to fair value meets weak quality (44/100). That raises the risk this is a value trap rather than a bargain. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (80.54 TWD to 152.80 TWD) leaves room in how you read the outcome.
Key figures of Foresee Pharmaceuticals Co Ltd
How large is the market capitalisation of Foresee Pharmaceuticals Co Ltd (6576)?
The market capitalisation of Foresee Pharmaceuticals Co Ltd is 12.6B TWD (≈ $397M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/E ratio of Foresee Pharmaceuticals Co Ltd (6576)?
The price-to-earnings ratio of Foresee Pharmaceuticals Co Ltd is 668.3. Price to earnings: how many years of current profit you pay for the stock. A P/E of 10 means ten years of profit.
What is the P/S ratio of Foresee Pharmaceuticals Co Ltd (6576)?
The price-to-sales ratio of Foresee Pharmaceuticals Co Ltd is 26.8 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Foresee Pharmaceuticals Co Ltd (6576)?
Earnings per share at Foresee Pharmaceuticals Co Ltd are 0.1200 TWD (price ÷ EPS = P/E 668.3). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Foresee Pharmaceuticals Co Ltd (6576)?
The net margin of Foresee Pharmaceuticals Co Ltd is 4.8% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Foresee Pharmaceuticals Co Ltd (6576)?
The return on equity (ROE) of Foresee Pharmaceuticals Co Ltd is 2.0% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Foresee Pharmaceuticals Co Ltd (6576)?
On an EBIT basis the return on assets of Foresee Pharmaceuticals Co Ltd is −46.9% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Foresee Pharmaceuticals Co Ltd (6576)?
The operating margin of Foresee Pharmaceuticals Co Ltd is −58.2% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Foresee Pharmaceuticals Co Ltd (6576)?
Revenue at Foresee Pharmaceuticals Co Ltd is growing +62.7% versus a year earlier (3y avg +12.7%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Foresee Pharmaceuticals Co Ltd (6576) generate?
The free cash flow of Foresee Pharmaceuticals Co Ltd is −858M TWD (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
Free · no account needed
Watch Foresee Pharmaceuticals Co Ltd in the live analysis
One click puts Foresee Pharmaceuticals Co Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
